BI 764198 is an oral, small molecule inhibitor of the transient receptor potential channel 6 (TRPC6), investigated for the potential to reduce COVID-19-related lung injury and progression to ARDS.
Recent:Ware.
Apr 6 2023 |
et al., Thorax, doi:10.1136/thorax-2022-219668 | TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial |
| 117% higher mortality (p=0.18), 12% higher progression (p=0.84), and 42% worse recovery (p=0.48). RCT 129 hospitalized COVID-19 patients requiring non-invasive oxygen support showing no benefit and potential harm with BI 764198 (TRPC6 inhibitor). The study was terminated early due to lack of efficacy and an imbalance of fatal events (.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.